Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520295 | 0.87 | — | — | |
| SCHEMBL6633187 | 0.85 | OPRM1 (0.32) | OPRM1NEK2HSD17B10 | |
| SCHEMBL21201862 | 0.72 | SOS1 (0.37) | SOS1SOS2 | |
| SCHEMBL2436684 | 0.71 | ALDH1A1 (0.37) | OPRM1NEK2 | |
| SCHEMBL31416318 | 0.69 | OPRM1 (0.31) | OPRM1NEK2 | |
| Hydrochloric Acid SCHEMBL31283258 | 0.69 | ALDH1A1 (0.36) | OPRM1NEK2 | |
| SCHEMBL31416408 | 0.69 | GRM5 (0.32) | OPRM1NEK2 | |
| SCHEMBL22576583 | 0.69 | — | — | |
| SCHEMBL6632040 | 0.68 | CYP3A4 (0.34) | — | |
| SCHEMBL20555997 | 0.68 | SRD5A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | SOS1 4643/4885SOS2 4542/4885OPRM1 4080/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | SOS1 4643/4885SOS2 4542/4885OPRM1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.